The weak consumer confidence report that hit U.S. stocks on Tuesday is having a lingering effect this Wednesday, with global stock markets falling and stock index futures pointing to another lower open on Wall Street.
Amgenreported quarterly results that outpaced what Wall Street was expecting, and the company boosted its outlook for its full-year profit. But the company's shares declined in extended trading.
Pfizer's acquisition of Wyeth will add to the pharmaceutical giant's diversity, which over time will help boost the company's stock, CEO Jeff Kindler told CNBC Tuesday.
Stocks pared some of their earlier losses but were still lower as disappointing results from Bank of America and General Electric eclipsed strong results from big techs.
Stocks pared some of their earlier losses but were still lower as disappointing results from Bank of America and General Electric eclipsed strong results from big techs.
Stocks skidded at the open Friday as disappointing results from Bank of America and General Electric eclipsed strong results from big techs. They slid further — with the Dow down 100 points — after a report showed a surprise drop in consumer sentiment.
The Dow pulled off a nearly 50-point gain Thursday after a topsy-turvy session as the boost from oil's rally ultimately beat out disappointment in earnings from Goldman Sachs and Citigroup.
Traders applied the brakes Thursday, a day after the Dow topped 10,000, as Goldman Sachs and Citigroup proved no match for Wall Street's inflated earnings expectations.
Stocks pared their losses Thursday after a third straight positive Philly Fed reading — the first time that's happened in two years. Stocks had opened lower after disappointment in earnings from Goldman Sachs and Citigroup.
After Wednesday's stellar market performance, stock index futures indicated a lower open for Wall Street on Thursday as investors take a breather and evaluate their next move.
Stocks rallied Wednesday, with the Dow homing in on 10,000, after JPMorgan and Intel got earnings season back on track and retail sales fell less than expected.
Pfizer today announced it's paying what amounts to chump change (a total of $115 million over time) for the rights to a biotech drug to treat a rare disease... Read More
With the health care debate continuing, how can investors make money in the sector? Barbara Ryan, managing director and senior pharmaceuticals analyst at Deutsche Bank Securities, and Charles Boorady, health care providers analyst at Citigroup, shared their insights.... Read More
Investors, patients and activists, no doubt, hope they won't have to put out a mayday distress call, but as Dendrama's fate would have it, the company announced today that the Food and Drug Administration has assigned May Day as its decision day for the prostate cancer treatment Provenge.... Read More